首页 > 最新文献

JAMA Network Open最新文献

英文 中文
Transitioning to Intravenous Tenecteplase for the Treatment of Acute Ischemic Stroke.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0555
Lina Palaiodimou, Georgios Tsivgoulis
{"title":"Transitioning to Intravenous Tenecteplase for the Treatment of Acute Ischemic Stroke.","authors":"Lina Palaiodimou, Georgios Tsivgoulis","doi":"10.1001/jamanetworkopen.2025.0555","DOIUrl":"10.1001/jamanetworkopen.2025.0555","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250555"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0548
Justin F Rousseau, Jeremy M Weber, Brooke Alhanti, Jeffrey L Saver, Steven R Messé, Lee H Schwamm, Gregg C Fonarow, Kevin N Sheth, Eric E Smith, Michael T Mullen, Gisele Sampaio Silva, Brian Mac Grory, Ying Xian, Steven J Warach
<p><strong>Importance: </strong>Tenecteplase is an alternative to alteplase for emergency treatment of acute ischemic stroke. However, limited data are available comparing their clinical effectiveness in routine clinical practice.</p><p><strong>Objective: </strong>To compare short-term effectiveness and safety outcomes for patients with ischemic stroke treated with intravenous tenecteplase vs alteplase.</p><p><strong>Design, setting, and participants: </strong>This comparative effectiveness study used data prospectively collected from July 1, 2020, through June 30, 2022, from the Get With The Guidelines-Stroke registry.</p><p><strong>Exposure: </strong>Consecutive patients with ischemic stroke treated with either tenecteplase or alteplase within 4.5 hours from last known well time were included.</p><p><strong>Main outcomes and measures: </strong>The primary end point was functional independence on discharge (modified Rankin Scale [mRS] score, 0-2). Secondary effectiveness end points included disability free at discharge (mRS score, 0-1), discharge home, and independent ambulation at discharge. Safety end points included symptomatic intracranial hemorrhage (sICH) within 36 hours and combined in-hospital mortality or hospice discharge. Generalized linear mixed models were fit to evaluate associations between exposure to tenecteplase (vs alteplase) and end points after adjustment for demographic, clinical, and hospital-level variables. Adjusted odds ratios (AORs) with 95% CIs were computed.</p><p><strong>Results: </strong>Among 79 550 patients treated with intravenous thrombolysis, the mean (SD) age was 68.6 (14.8) years, 38 596 (48.5%) were female, and the median National Institutes of Health Stroke Scale (NIHSS) score was 7 (IQR, 4-13). Of these patients, 9465 (11.9%) received tenecteplase (mean [SD] age, 69.6 [14.7] years; median NIHSS score, 7 [IQR, 4-14]; 4504 [47.6%] female) and 70 085 (88.1%) received alteplase (mean [SD] age, 68.5 [14.8] years; median NIHSS score, 7 [IQR, 4-13]; 34 092 [48.6%] female). After adjustment for covariates, no significant differences were found between tenecteplase and alteplase in effectiveness or safety outcomes for the overall cohort, including functional independence at discharge (AOR, 1.00; 95% CI, 0.93-1.07), sICH (AOR, 0.96; 95% CI, 0.83-1.11), and in-hospital mortality or hospice discharge (AOR, 0.98; 95% CI, 0.89-1.07), but significant improvement was found in discharge home (AOR, 1.26; 95% CI, 1.03-1.53), in-hospital mortality (AOR, 0.63; 95% CI, 0.47-0.85), and composite in-hospital mortality or hospice discharge (AOR, 0.78; 95% CI, 0.62-0.97) among those who were eligible for but did not undergo endovascular thrombectomy.</p><p><strong>Conclusions and relevance: </strong>This large, nationwide comparative effectiveness study using data from routine clinical practice demonstrated similar effectiveness and safety outcomes with tenecteplase compared with alteplase in patients with acute ischemic stroke. T
{"title":"Short-Term Safety and Effectiveness for Tenecteplase and Alteplase in Acute Ischemic Stroke.","authors":"Justin F Rousseau, Jeremy M Weber, Brooke Alhanti, Jeffrey L Saver, Steven R Messé, Lee H Schwamm, Gregg C Fonarow, Kevin N Sheth, Eric E Smith, Michael T Mullen, Gisele Sampaio Silva, Brian Mac Grory, Ying Xian, Steven J Warach","doi":"10.1001/jamanetworkopen.2025.0548","DOIUrl":"10.1001/jamanetworkopen.2025.0548","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Tenecteplase is an alternative to alteplase for emergency treatment of acute ischemic stroke. However, limited data are available comparing their clinical effectiveness in routine clinical practice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To compare short-term effectiveness and safety outcomes for patients with ischemic stroke treated with intravenous tenecteplase vs alteplase.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This comparative effectiveness study used data prospectively collected from July 1, 2020, through June 30, 2022, from the Get With The Guidelines-Stroke registry.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposure: &lt;/strong&gt;Consecutive patients with ischemic stroke treated with either tenecteplase or alteplase within 4.5 hours from last known well time were included.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary end point was functional independence on discharge (modified Rankin Scale [mRS] score, 0-2). Secondary effectiveness end points included disability free at discharge (mRS score, 0-1), discharge home, and independent ambulation at discharge. Safety end points included symptomatic intracranial hemorrhage (sICH) within 36 hours and combined in-hospital mortality or hospice discharge. Generalized linear mixed models were fit to evaluate associations between exposure to tenecteplase (vs alteplase) and end points after adjustment for demographic, clinical, and hospital-level variables. Adjusted odds ratios (AORs) with 95% CIs were computed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 79 550 patients treated with intravenous thrombolysis, the mean (SD) age was 68.6 (14.8) years, 38 596 (48.5%) were female, and the median National Institutes of Health Stroke Scale (NIHSS) score was 7 (IQR, 4-13). Of these patients, 9465 (11.9%) received tenecteplase (mean [SD] age, 69.6 [14.7] years; median NIHSS score, 7 [IQR, 4-14]; 4504 [47.6%] female) and 70 085 (88.1%) received alteplase (mean [SD] age, 68.5 [14.8] years; median NIHSS score, 7 [IQR, 4-13]; 34 092 [48.6%] female). After adjustment for covariates, no significant differences were found between tenecteplase and alteplase in effectiveness or safety outcomes for the overall cohort, including functional independence at discharge (AOR, 1.00; 95% CI, 0.93-1.07), sICH (AOR, 0.96; 95% CI, 0.83-1.11), and in-hospital mortality or hospice discharge (AOR, 0.98; 95% CI, 0.89-1.07), but significant improvement was found in discharge home (AOR, 1.26; 95% CI, 1.03-1.53), in-hospital mortality (AOR, 0.63; 95% CI, 0.47-0.85), and composite in-hospital mortality or hospice discharge (AOR, 0.78; 95% CI, 0.62-0.97) among those who were eligible for but did not undergo endovascular thrombectomy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;This large, nationwide comparative effectiveness study using data from routine clinical practice demonstrated similar effectiveness and safety outcomes with tenecteplase compared with alteplase in patients with acute ischemic stroke. T","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250548"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapy Dogs for Anxiety in Children in the Emergency Department: A Randomized Clinical Trial.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0636
Heather P Kelker, Huma K Siddiqui, Alan M Beck, Jeffrey A Kline
<p><strong>Importance: </strong>Prior evidence suggests that the use of therapy dogs in emergency care reduces anxiety in adults, but no trial has tested the use of therapy dogs in emergency care of children.</p><p><strong>Objective: </strong>To examine whether adjunctive use of therapy dogs in standard child-life therapy reduces child-reported and parent-reported child anxiety in a pediatric emergency department (ED).</p><p><strong>Design, setting, and participants: </strong>This randomized clinical trial was conducted from February 1, 2023, to June 30, 2024, at an academic pediatric ED. Children (aged 5-17 years) with suspected moderate to high anxiety were included.</p><p><strong>Intervention: </strong>All participants received standard child-life therapy, and the intervention group was randomly assigned to have exposure to a therapy dog and handler for approximately 10 minutes.</p><p><strong>Main outcomes and measures: </strong>Anxiety was measured using the 0- to 10-point FACES scale (with 0 indicating no anxiety and 10 indicating very severe anxiety) and salivary cortisol concentrations. Measurements were obtained at baseline (T0), 45 minutes (T1), and 120 minutes (T2) for both child and parents.</p><p><strong>Results: </strong>A total of 80 patients (mean [SD] age, 10.9 [3.8] years; 45 [56%] female) were enrolled (40 in the control group and 40 in the intervention group). At T0, the mean (SD) FACES scores were 5.4 (2.8) for child report and 6.4 (2.4) for parent report; the means were not different between groups. From T0 to T1, child-reported anxiety changed by a mean (SD) of -1.5 (3.4) points in the control group vs -2.7 (2.5) points in the intervention group (P = .02, Mann-Whitney U test); similarly, mean (SD) parent-estimated child anxiety changed by -1.8 (2.7) points in the control group vs -3.2 (2.3) points in the intervention group (P = .008). A total of 9 children (23%) in the control group had a greater than 2.5-point decrease in FACES score vs 18 (46%) in intervention group (P = .04, Fisher test). At T2, mean (SD) child-reported FACES scores decreased to 3.6 (3.4) points in the control group and 3.0 (2.7) points in the intervention group (P = .70). A total of 14 control participants (35%) received ketamine, midazolam, lorazepam, or droperidol vs 7 (18%) in the intervention group (P = .08, Fisher test). Child and parent salivary cortisol decreased from T0 to T1 in both groups but was not different between groups. Parental salivary cortisol was significantly consistently higher than their children's salivary cortisol (P < .001, unpaired t test, for comparisons of child vs parent at T0 and T1 in both groups).</p><p><strong>Conclusions and relevance: </strong>This study of adjunctive use of therapy dogs in standard child-life therapy found a modest but significantly greater reduction in both child-reported and parental-reported child anxiety in the pediatric ED for the intervention vs control group. These findings support the use of t
{"title":"Therapy Dogs for Anxiety in Children in the Emergency Department: A Randomized Clinical Trial.","authors":"Heather P Kelker, Huma K Siddiqui, Alan M Beck, Jeffrey A Kline","doi":"10.1001/jamanetworkopen.2025.0636","DOIUrl":"10.1001/jamanetworkopen.2025.0636","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Prior evidence suggests that the use of therapy dogs in emergency care reduces anxiety in adults, but no trial has tested the use of therapy dogs in emergency care of children.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To examine whether adjunctive use of therapy dogs in standard child-life therapy reduces child-reported and parent-reported child anxiety in a pediatric emergency department (ED).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This randomized clinical trial was conducted from February 1, 2023, to June 30, 2024, at an academic pediatric ED. Children (aged 5-17 years) with suspected moderate to high anxiety were included.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Intervention: &lt;/strong&gt;All participants received standard child-life therapy, and the intervention group was randomly assigned to have exposure to a therapy dog and handler for approximately 10 minutes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Anxiety was measured using the 0- to 10-point FACES scale (with 0 indicating no anxiety and 10 indicating very severe anxiety) and salivary cortisol concentrations. Measurements were obtained at baseline (T0), 45 minutes (T1), and 120 minutes (T2) for both child and parents.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 80 patients (mean [SD] age, 10.9 [3.8] years; 45 [56%] female) were enrolled (40 in the control group and 40 in the intervention group). At T0, the mean (SD) FACES scores were 5.4 (2.8) for child report and 6.4 (2.4) for parent report; the means were not different between groups. From T0 to T1, child-reported anxiety changed by a mean (SD) of -1.5 (3.4) points in the control group vs -2.7 (2.5) points in the intervention group (P = .02, Mann-Whitney U test); similarly, mean (SD) parent-estimated child anxiety changed by -1.8 (2.7) points in the control group vs -3.2 (2.3) points in the intervention group (P = .008). A total of 9 children (23%) in the control group had a greater than 2.5-point decrease in FACES score vs 18 (46%) in intervention group (P = .04, Fisher test). At T2, mean (SD) child-reported FACES scores decreased to 3.6 (3.4) points in the control group and 3.0 (2.7) points in the intervention group (P = .70). A total of 14 control participants (35%) received ketamine, midazolam, lorazepam, or droperidol vs 7 (18%) in the intervention group (P = .08, Fisher test). Child and parent salivary cortisol decreased from T0 to T1 in both groups but was not different between groups. Parental salivary cortisol was significantly consistently higher than their children's salivary cortisol (P &lt; .001, unpaired t test, for comparisons of child vs parent at T0 and T1 in both groups).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;This study of adjunctive use of therapy dogs in standard child-life therapy found a modest but significantly greater reduction in both child-reported and parental-reported child anxiety in the pediatric ED for the intervention vs control group. These findings support the use of t","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250636"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Building Biobanks to Drive Biomedical Research and Genomically Informed Care.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0925
Heidi L Rehm
{"title":"Building Biobanks to Drive Biomedical Research and Genomically Informed Care.","authors":"Heidi L Rehm","doi":"10.1001/jamanetworkopen.2025.0925","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2025.0925","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250925"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers to Deprescribing Benzodiazepines in Older Adults in a Survey of European Physicians.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2024.59883
Vladyslav Shapoval, Marie de Saint Hubert, Perrine Evrard, François-Xavier Sibille, Carole E Aubert, Lucy Bolt, Vagioula Tsoutsi, Pinelopi Kollia, Antoni Salvà, Ramon Miralles, Adam Wichniak, Katarzyna Gustavsson, Torgeir Bruun Wyller, Enrico Callegari, Jeremy M Grimshaw, Justin Presseau, Séverine Henrard, Anne Spinewine
<p><strong>Importance: </strong>The use of benzodiazepine receptor agonists (BZRA) poses serious health risks to older adults. Although several guidelines recommend deprescribing, implementation in clinical practice remains limited.</p><p><strong>Objective: </strong>To identify physicians' barriers to and enablers of deprescribing BZRA in adults aged 65 years and older taking a BZRA for sleep problems; to determine factors associated with hospital physicians' intention to deprescribe BZRA and their self-reported routine BZRA deprescribing.</p><p><strong>Design, setting, and participants: </strong>This survey study included hospital physicians and general practitioners (GPs) working across 6 European Countries (Belgium, Greece, Norway, Poland, Spain, and Switzerland) between December 2022 and March 2023.</p><p><strong>Main outcomes and measures: </strong>Barriers identification via a 35-item questionnaire based upon the Theoretical Domains Framework (TDF). Responses were categorized as major barriers, moderate barriers, and enablers based on their mean scores. Multivariable logistic regressions were used to identify background characteristics and TDF-based domains associated with hospital physicians' intention to deprescribe and self-reported routine deprescribing.</p><p><strong>Results: </strong>Questionnaires from 240 hospital physicians and 96 GPs were analyzed. Most participants were women: 144 (61.0%) hospital physicians and 52 (54.2%) GPs. In terms of experience, the most common reported time in practice was less than 5 years for hospital physicians (76 [31.7%]) and between 10 and 14 years for GPs (35 [36.5%]). Most reported deprescribing BZRA routinely (135 hospital physicians [57.2%] and 66 GPs [72.5%]). Major barriers (and TDF domains) were similar for hospital physicians and GPs across the 6 countries. These barriers included: lack of training (skills), low self-efficacy (beliefs about capabilities), prioritization of other health issues (goals), frustration with the challenges of deprescribing (emotions), insufficient staff and time, absence of local policies (environmental context and resources), and reluctance from patients (social influence). Intention to deprescribe was significantly associated with country, occupation type, and 5 TDF domains: memory, attention, and decision process (odds ratio [OR], 1.70; 95% Ci, 1.22-2.40); social and/or professional role and identity (OR, 5.92; 95% CI, 3.28-11.07); beliefs about capabilities (OR, 2.35; 95% CI, 1.55-3.63); beliefs about consequences (OR, 3.00; 95% CI, 1.61-5.71); and reinforcement (OR, 1.49; 95% CI, 1.05-2.15). Routine deprescribing was significantly associated with 3 TDF domains: memory, attention, and decision processes; intentions; and emotions.</p><p><strong>Conclusion: </strong>In this theory-based survey study of physicians, physicians and general practitioners described numerous barriers to deprescribing BZRA in older adults. Our findings indicate that effective deprescribi
{"title":"Barriers to Deprescribing Benzodiazepines in Older Adults in a Survey of European Physicians.","authors":"Vladyslav Shapoval, Marie de Saint Hubert, Perrine Evrard, François-Xavier Sibille, Carole E Aubert, Lucy Bolt, Vagioula Tsoutsi, Pinelopi Kollia, Antoni Salvà, Ramon Miralles, Adam Wichniak, Katarzyna Gustavsson, Torgeir Bruun Wyller, Enrico Callegari, Jeremy M Grimshaw, Justin Presseau, Séverine Henrard, Anne Spinewine","doi":"10.1001/jamanetworkopen.2024.59883","DOIUrl":"10.1001/jamanetworkopen.2024.59883","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;The use of benzodiazepine receptor agonists (BZRA) poses serious health risks to older adults. Although several guidelines recommend deprescribing, implementation in clinical practice remains limited.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To identify physicians' barriers to and enablers of deprescribing BZRA in adults aged 65 years and older taking a BZRA for sleep problems; to determine factors associated with hospital physicians' intention to deprescribe BZRA and their self-reported routine BZRA deprescribing.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This survey study included hospital physicians and general practitioners (GPs) working across 6 European Countries (Belgium, Greece, Norway, Poland, Spain, and Switzerland) between December 2022 and March 2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Barriers identification via a 35-item questionnaire based upon the Theoretical Domains Framework (TDF). Responses were categorized as major barriers, moderate barriers, and enablers based on their mean scores. Multivariable logistic regressions were used to identify background characteristics and TDF-based domains associated with hospital physicians' intention to deprescribe and self-reported routine deprescribing.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Questionnaires from 240 hospital physicians and 96 GPs were analyzed. Most participants were women: 144 (61.0%) hospital physicians and 52 (54.2%) GPs. In terms of experience, the most common reported time in practice was less than 5 years for hospital physicians (76 [31.7%]) and between 10 and 14 years for GPs (35 [36.5%]). Most reported deprescribing BZRA routinely (135 hospital physicians [57.2%] and 66 GPs [72.5%]). Major barriers (and TDF domains) were similar for hospital physicians and GPs across the 6 countries. These barriers included: lack of training (skills), low self-efficacy (beliefs about capabilities), prioritization of other health issues (goals), frustration with the challenges of deprescribing (emotions), insufficient staff and time, absence of local policies (environmental context and resources), and reluctance from patients (social influence). Intention to deprescribe was significantly associated with country, occupation type, and 5 TDF domains: memory, attention, and decision process (odds ratio [OR], 1.70; 95% Ci, 1.22-2.40); social and/or professional role and identity (OR, 5.92; 95% CI, 3.28-11.07); beliefs about capabilities (OR, 2.35; 95% CI, 1.55-3.63); beliefs about consequences (OR, 3.00; 95% CI, 1.61-5.71); and reinforcement (OR, 1.49; 95% CI, 1.05-2.15). Routine deprescribing was significantly associated with 3 TDF domains: memory, attention, and decision processes; intentions; and emotions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In this theory-based survey study of physicians, physicians and general practitioners described numerous barriers to deprescribing BZRA in older adults. Our findings indicate that effective deprescribi","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e2459883"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
No Surprises Act Independent Dispute Resolution Outcomes for Air Ambulances. 空中救护无意外法案》的独立争议解决结果。
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2024.62404
Erin L Duffy, Christopher Garmon
<p><strong>Importance: </strong>The No Surprises Act (NSA) banned surprise patient balance bills and established a binding arbitration system to resolve payment disputes between insurers and health care providers (eg, clinicians, hospitals, air ambulance organizations) for certain services, including air ambulance transportation. Understanding use and results of this new independent dispute resolution (IDR) system can inform ongoing adjustments to its implementation.</p><p><strong>Objective: </strong>To describe the involved parties and outcomes of air ambulance NSA IDR cases.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study assessed cases arbitrated through NSA IDR in 2023 as reported by the Centers for Medicare & Medicaid Services. Participants included air ambulance organizations and commercial insurers. Data were analyzed between August 1 and September 1, 2024.</p><p><strong>Exposures: </strong>Fixed-wing and rotary transport disputes arbitrated under the NSA IDR system.</p><p><strong>Main outcomes and measures: </strong>The activation components of fixed-wing and rotary transport disputes were evaluated with data from 2 distinct public files: (1) disclosed parties and outcomes relative to qualifying payment amounts (QPAs), the insurers' median of contracted rates for similar services in the region among similar health plans; and (2) monetary measures but without parties. The first file describes the insurers and organizations involved, including their ownership status, as well as the prevailing party and the offers and decisions relative to QPA. The second file describes QPAs, offers, and decisions monetarily and these are compared with Medicare's urban allowed amount.</p><p><strong>Results: </strong>There were 5678 IDR cases in 2023, comprising disputes for 4935 rotary and 743 fixed-wing transports. Air ambulance organizations offered a mean (SD) of 3.18 (4.20) times QPA, and insurers offered 1.39 (3.89) times QPA. Organizations won 4905 cases (86.4%) at a mean (SD) of 2.95 (4.12) times the QPA. A total of 3478 cases (61.3%) involved organizations owned by private equity investors, and these cases had higher prevailing offers relative to the QPA. Due to data suppression, analysis of financial measures was possible for 2897 of 5983 activation cases (48.4%), among which the mean (SD) QPA offer was $15 561.08 ($9730.97) (3.74 [2.31] times Medicare), and the winning offer was $32 463.70 ($9987.17) (7.82 [2.39] times Medicare).</p><p><strong>Conclusions and relevance: </strong>In this cross-sectional study of air ambulance payment disputes, air ambulance organizations won most cases, requiring insurers to pay more in these cases. Notably, the NSA does not require changes to patient cost-sharing based on IDR outcomes. Assessment of the financial metrics and outcomes of air ambulance cases was limited due to missing and masked information. Continued monitoring of air ambulance IDR cases is needed to assess the i
{"title":"No Surprises Act Independent Dispute Resolution Outcomes for Air Ambulances.","authors":"Erin L Duffy, Christopher Garmon","doi":"10.1001/jamanetworkopen.2024.62404","DOIUrl":"10.1001/jamanetworkopen.2024.62404","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;The No Surprises Act (NSA) banned surprise patient balance bills and established a binding arbitration system to resolve payment disputes between insurers and health care providers (eg, clinicians, hospitals, air ambulance organizations) for certain services, including air ambulance transportation. Understanding use and results of this new independent dispute resolution (IDR) system can inform ongoing adjustments to its implementation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To describe the involved parties and outcomes of air ambulance NSA IDR cases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This cross-sectional study assessed cases arbitrated through NSA IDR in 2023 as reported by the Centers for Medicare & Medicaid Services. Participants included air ambulance organizations and commercial insurers. Data were analyzed between August 1 and September 1, 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposures: &lt;/strong&gt;Fixed-wing and rotary transport disputes arbitrated under the NSA IDR system.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The activation components of fixed-wing and rotary transport disputes were evaluated with data from 2 distinct public files: (1) disclosed parties and outcomes relative to qualifying payment amounts (QPAs), the insurers' median of contracted rates for similar services in the region among similar health plans; and (2) monetary measures but without parties. The first file describes the insurers and organizations involved, including their ownership status, as well as the prevailing party and the offers and decisions relative to QPA. The second file describes QPAs, offers, and decisions monetarily and these are compared with Medicare's urban allowed amount.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;There were 5678 IDR cases in 2023, comprising disputes for 4935 rotary and 743 fixed-wing transports. Air ambulance organizations offered a mean (SD) of 3.18 (4.20) times QPA, and insurers offered 1.39 (3.89) times QPA. Organizations won 4905 cases (86.4%) at a mean (SD) of 2.95 (4.12) times the QPA. A total of 3478 cases (61.3%) involved organizations owned by private equity investors, and these cases had higher prevailing offers relative to the QPA. Due to data suppression, analysis of financial measures was possible for 2897 of 5983 activation cases (48.4%), among which the mean (SD) QPA offer was $15 561.08 ($9730.97) (3.74 [2.31] times Medicare), and the winning offer was $32 463.70 ($9987.17) (7.82 [2.39] times Medicare).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In this cross-sectional study of air ambulance payment disputes, air ambulance organizations won most cases, requiring insurers to pay more in these cases. Notably, the NSA does not require changes to patient cost-sharing based on IDR outcomes. Assessment of the financial metrics and outcomes of air ambulance cases was limited due to missing and masked information. Continued monitoring of air ambulance IDR cases is needed to assess the i","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e2462404"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative Aspiration Pneumonia Among Adults Using GLP-1 Receptor Agonists.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0081
Yuan-Hsin Chen, Thomas Zink, Ya-Wen Chen, Darren Z Nin, Carl T Talmo, Brian L Hollenbeck, Andrew R Grant, Ruijia Niu, David C Chang, Eric L Smith

Importance: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been increasingly prescribed for weight management in recent years. However, little is known about whether preoperative GLP-1 RA use is associated with a greater risk of complications after surgery.

Objective: To investigate whether preoperative GLP-1 RA use is associated with postoperative aspiration pneumonia among patients undergoing common surgical procedures.

Design, setting, and participants: This retrospective cohort study, conducted using MarketScan commercial claims databases, included patients who underwent 1 of 14 common surgical procedures from April 1, 2020, to September 30, 2022. Individuals who were younger than 18 years, underwent multiple surgical procedures, or had a preoperative history of pneumonia or acute respiratory failure in the 90 days preceding surgery were excluded. Data were analyzed from December 2023 to March 2024.

Main outcome and measures: The primary outcome was aspiration pneumonia in the 30-day postoperative period. Multivariable logistic regressions were performed, adjusting for patient and surgical characteristics.

Results: This study included 366 476 patients (median age, 53 years [IQR, 43-62 years]), of whom 56.4% were women. In the cohort, 5931 patients (1.6%) had a preoperative prescription for a GLP-1 RA. Patients using GLP-1 RAs were more likely to be female (3502 [59.0%] vs 203 288 [56.4%]) and diagnosed with both obesity and diabetes (2819 [47.5%] vs 24 635 [6.8%]) compared with nonusers. Adjusted analysis showed no significant differences in the odds of postoperative pneumonia (odds ratio, 0.78; 95% CI, 0.57-1.06; P = .12) between GLP-1 RA users and nonusers.

Conclusions and relevance: This cohort study found no significant association between the preoperative use of GLP-1 RAs and short-term postoperative aspiration pneumonia despite growing concerns about the adverse effects of these medications after surgery. This finding suggests that it may be beneficial to reassess the preoperative withholding guidelines for GLP-1 RAs.

{"title":"Postoperative Aspiration Pneumonia Among Adults Using GLP-1 Receptor Agonists.","authors":"Yuan-Hsin Chen, Thomas Zink, Ya-Wen Chen, Darren Z Nin, Carl T Talmo, Brian L Hollenbeck, Andrew R Grant, Ruijia Niu, David C Chang, Eric L Smith","doi":"10.1001/jamanetworkopen.2025.0081","DOIUrl":"10.1001/jamanetworkopen.2025.0081","url":null,"abstract":"<p><strong>Importance: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been increasingly prescribed for weight management in recent years. However, little is known about whether preoperative GLP-1 RA use is associated with a greater risk of complications after surgery.</p><p><strong>Objective: </strong>To investigate whether preoperative GLP-1 RA use is associated with postoperative aspiration pneumonia among patients undergoing common surgical procedures.</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort study, conducted using MarketScan commercial claims databases, included patients who underwent 1 of 14 common surgical procedures from April 1, 2020, to September 30, 2022. Individuals who were younger than 18 years, underwent multiple surgical procedures, or had a preoperative history of pneumonia or acute respiratory failure in the 90 days preceding surgery were excluded. Data were analyzed from December 2023 to March 2024.</p><p><strong>Main outcome and measures: </strong>The primary outcome was aspiration pneumonia in the 30-day postoperative period. Multivariable logistic regressions were performed, adjusting for patient and surgical characteristics.</p><p><strong>Results: </strong>This study included 366 476 patients (median age, 53 years [IQR, 43-62 years]), of whom 56.4% were women. In the cohort, 5931 patients (1.6%) had a preoperative prescription for a GLP-1 RA. Patients using GLP-1 RAs were more likely to be female (3502 [59.0%] vs 203 288 [56.4%]) and diagnosed with both obesity and diabetes (2819 [47.5%] vs 24 635 [6.8%]) compared with nonusers. Adjusted analysis showed no significant differences in the odds of postoperative pneumonia (odds ratio, 0.78; 95% CI, 0.57-1.06; P = .12) between GLP-1 RA users and nonusers.</p><p><strong>Conclusions and relevance: </strong>This cohort study found no significant association between the preoperative use of GLP-1 RAs and short-term postoperative aspiration pneumonia despite growing concerns about the adverse effects of these medications after surgery. This finding suggests that it may be beneficial to reassess the preoperative withholding guidelines for GLP-1 RAs.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250081"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative Outcomes Following Preweekend Surgery.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2024.58794
Sanjana Ranganathan, Carlos Riveros, Yusuke Tsugawa, Michael Geng, Vatsala Mundra, Zachary Melchiode, Bheeshma Ravi, Natalie Coburn, Angela Jerath, Allan S Detsky, Christopher J D Wallis, Raj Satkunasivam

Importance: The phenomenon of a weekend effect refers to a higher potential for adverse outcomes in patients receiving care over the weekend. Few prior studies have comprehensively investigated the effects of postoperative weekend care on surgical outcomes in a generalizable cohort.

Objective: To examine differences in short-term and long-term postoperative outcomes of patients undergoing surgical procedures immediately before vs after the weekend.

Design, setting, and participants: This is a population-based, retrospective cohort secondary analysis of adult patients in Ontario, Canada, undergoing 1 of 25 common surgical procedures between January 1, 2007, to December 31, 2019, with 1 year of follow-up. Data analysis was performed from October to November 2022.

Exposure: Undergoing surgery before (1 day before) vs after (1 day after) the weekend.

Main outcomes and measures: The primary outcome was a composite of death, readmission, and complications at 30 days, 90 days, and 1 year. Multivariable generalized estimating equations with an independent correlation structure, accounting for covariates, with clustering on surgical procedure were used to estimate the association between day of surgery in relation to the weekend and the outcomes.

Results: Of the 429 691 patients (mean [SD] age, 58.6 [16.9] years; 270 002 female patients [62.8%]) in the study cohort, 199 744 (46.5%) underwent surgery before the weekend, and 229 947 (53.5%) underwent surgery after the weekend. Patients in the preweekend group were more likely than those in the postweekend group to experience the composite outcome of death, complications, and readmissions at 30 days (adjusted odds ratio [aOR], 1.05; 95% CI, 1.02-1.08), 90 days (aOR, 1.06; 95% CI, 1.03-1.09), and 1 year (aOR, 1.05; 95% CI, 1.02-1.09) after surgery. Odds of mortality were increased in the preweekend group vs the postweekend group at 30 days (aOR, 1.09; 95% CI, 1.03-1.16), 90 days (aOR, 1.10; 95% CI, 1.03-1.17), and 1 year (aOR, 1.12; 95% CI, 1.08-1.17).

Conclusions and relevance: In this retrospective multi-institutional study, patients who underwent surgery immediately preceding the weekend had a significantly increased risk of complications, readmissions, and mortality compared with those treated after the weekend. Further study is needed to understand differences in care that may underpin these observations and ensure that patients receive high-quality care regardless of the day of the week.

{"title":"Postoperative Outcomes Following Preweekend Surgery.","authors":"Sanjana Ranganathan, Carlos Riveros, Yusuke Tsugawa, Michael Geng, Vatsala Mundra, Zachary Melchiode, Bheeshma Ravi, Natalie Coburn, Angela Jerath, Allan S Detsky, Christopher J D Wallis, Raj Satkunasivam","doi":"10.1001/jamanetworkopen.2024.58794","DOIUrl":"10.1001/jamanetworkopen.2024.58794","url":null,"abstract":"<p><strong>Importance: </strong>The phenomenon of a weekend effect refers to a higher potential for adverse outcomes in patients receiving care over the weekend. Few prior studies have comprehensively investigated the effects of postoperative weekend care on surgical outcomes in a generalizable cohort.</p><p><strong>Objective: </strong>To examine differences in short-term and long-term postoperative outcomes of patients undergoing surgical procedures immediately before vs after the weekend.</p><p><strong>Design, setting, and participants: </strong>This is a population-based, retrospective cohort secondary analysis of adult patients in Ontario, Canada, undergoing 1 of 25 common surgical procedures between January 1, 2007, to December 31, 2019, with 1 year of follow-up. Data analysis was performed from October to November 2022.</p><p><strong>Exposure: </strong>Undergoing surgery before (1 day before) vs after (1 day after) the weekend.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was a composite of death, readmission, and complications at 30 days, 90 days, and 1 year. Multivariable generalized estimating equations with an independent correlation structure, accounting for covariates, with clustering on surgical procedure were used to estimate the association between day of surgery in relation to the weekend and the outcomes.</p><p><strong>Results: </strong>Of the 429 691 patients (mean [SD] age, 58.6 [16.9] years; 270 002 female patients [62.8%]) in the study cohort, 199 744 (46.5%) underwent surgery before the weekend, and 229 947 (53.5%) underwent surgery after the weekend. Patients in the preweekend group were more likely than those in the postweekend group to experience the composite outcome of death, complications, and readmissions at 30 days (adjusted odds ratio [aOR], 1.05; 95% CI, 1.02-1.08), 90 days (aOR, 1.06; 95% CI, 1.03-1.09), and 1 year (aOR, 1.05; 95% CI, 1.02-1.09) after surgery. Odds of mortality were increased in the preweekend group vs the postweekend group at 30 days (aOR, 1.09; 95% CI, 1.03-1.16), 90 days (aOR, 1.10; 95% CI, 1.03-1.17), and 1 year (aOR, 1.12; 95% CI, 1.08-1.17).</p><p><strong>Conclusions and relevance: </strong>In this retrospective multi-institutional study, patients who underwent surgery immediately preceding the weekend had a significantly increased risk of complications, readmissions, and mortality compared with those treated after the weekend. Further study is needed to understand differences in care that may underpin these observations and ensure that patients receive high-quality care regardless of the day of the week.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e2458794"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trajectories of Sleep Duration, Sleep Onset Timing, and Continuous Glucose Monitoring in Adults.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0114
Luqi Shen, Bang-Yan Li, Wanglong Gou, Xinxiu Liang, Haili Zhong, Congmei Xiao, Ruiqi Shi, Zelei Miao, Yan Yan, Yuanqing Fu, Yu-Ming Chen, Ju-Sheng Zheng

Importance: Understanding the interplay between trajectories of sleep duration, sleep onset timing, and glycemic dynamics is crucial for improving preventive strategies against diabetes and related metabolic diseases.

Objective: To examine the associations of sleep duration and onset timing trajectories with continuous glucose monitoring (CGM)-derived glycemic metrics in adults.

Design, setting, and participants: This cohort study analyzed data collected from January 2014 to December 2023 in the Guangzhou Nutrition and Health Study, a prospective cohort in Guangdong province, China, among participants aged 46 to 83. Participants who had repeated sleep assessments at several study visits and were equipped with CGM devices at the last visit were included. Data analyses were conducted between January and June 2024.

Exposures: The trajectories of sleep duration and onset timing were constructed using self-report sleep duration and sleep onset timing, recorded at multiple study visit points.

Main outcomes and measures: Measurements of glycemic variability and glycemic control were collected using a masked CGM device worn by patients for 14 consecutive days. Huber robust regression models were used to assess the associations between sleep trajectories and CGM-derived metrics.

Results: In this study of 1156 participants (mean [SD] age, 63.0 [5.1] years, 816 [70.6%] women), we identified 4 distinct sleep duration trajectory groups: severe inadequate, moderate inadequate, mild inadequate, and adequate. Severe sleep inadequacy was associated with an increment of glycemic variability indicators: 2.87% (95% CI, 1.23%-4.50%) for coefficient of variation and 0.06 (95% CI, 0.02-0.09) mmol/L for mean of daily differences. We found 2 trajectories of sleep onset timing: persistent early and persistent late groups. Late sleep onset was associated with larger coefficient of variation (β = 1.18%; 95% CI, 0.36%-2.01%) and mean of daily differences (β = 0.02 mmol/L; 95% CI, 0.01-0.04 mmol/L). Inappropriate sleep duration and timing trajectories in combination were associated with greater glycemic variability.

Conclusions and relevance: In this cohort study of middle-aged and older participants, persistent inadequate sleep duration and late sleep onset, whether alone or in combination, were associated with greater glycemic variability. These findings emphasize the importance of considering both sleep duration and timing for optimizing glycemic control in the general population.

{"title":"Trajectories of Sleep Duration, Sleep Onset Timing, and Continuous Glucose Monitoring in Adults.","authors":"Luqi Shen, Bang-Yan Li, Wanglong Gou, Xinxiu Liang, Haili Zhong, Congmei Xiao, Ruiqi Shi, Zelei Miao, Yan Yan, Yuanqing Fu, Yu-Ming Chen, Ju-Sheng Zheng","doi":"10.1001/jamanetworkopen.2025.0114","DOIUrl":"10.1001/jamanetworkopen.2025.0114","url":null,"abstract":"<p><strong>Importance: </strong>Understanding the interplay between trajectories of sleep duration, sleep onset timing, and glycemic dynamics is crucial for improving preventive strategies against diabetes and related metabolic diseases.</p><p><strong>Objective: </strong>To examine the associations of sleep duration and onset timing trajectories with continuous glucose monitoring (CGM)-derived glycemic metrics in adults.</p><p><strong>Design, setting, and participants: </strong>This cohort study analyzed data collected from January 2014 to December 2023 in the Guangzhou Nutrition and Health Study, a prospective cohort in Guangdong province, China, among participants aged 46 to 83. Participants who had repeated sleep assessments at several study visits and were equipped with CGM devices at the last visit were included. Data analyses were conducted between January and June 2024.</p><p><strong>Exposures: </strong>The trajectories of sleep duration and onset timing were constructed using self-report sleep duration and sleep onset timing, recorded at multiple study visit points.</p><p><strong>Main outcomes and measures: </strong>Measurements of glycemic variability and glycemic control were collected using a masked CGM device worn by patients for 14 consecutive days. Huber robust regression models were used to assess the associations between sleep trajectories and CGM-derived metrics.</p><p><strong>Results: </strong>In this study of 1156 participants (mean [SD] age, 63.0 [5.1] years, 816 [70.6%] women), we identified 4 distinct sleep duration trajectory groups: severe inadequate, moderate inadequate, mild inadequate, and adequate. Severe sleep inadequacy was associated with an increment of glycemic variability indicators: 2.87% (95% CI, 1.23%-4.50%) for coefficient of variation and 0.06 (95% CI, 0.02-0.09) mmol/L for mean of daily differences. We found 2 trajectories of sleep onset timing: persistent early and persistent late groups. Late sleep onset was associated with larger coefficient of variation (β = 1.18%; 95% CI, 0.36%-2.01%) and mean of daily differences (β = 0.02 mmol/L; 95% CI, 0.01-0.04 mmol/L). Inappropriate sleep duration and timing trajectories in combination were associated with greater glycemic variability.</p><p><strong>Conclusions and relevance: </strong>In this cohort study of middle-aged and older participants, persistent inadequate sleep duration and late sleep onset, whether alone or in combination, were associated with greater glycemic variability. These findings emphasize the importance of considering both sleep duration and timing for optimizing glycemic control in the general population.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250114"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists.
IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1001/jamanetworkopen.2025.0802
Omer S Ashruf, Jasmin Hundal, Ali Mushtaq, David C Kaelber, Faiz Anwer, Abhay Singh
{"title":"Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists.","authors":"Omer S Ashruf, Jasmin Hundal, Ali Mushtaq, David C Kaelber, Faiz Anwer, Abhay Singh","doi":"10.1001/jamanetworkopen.2025.0802","DOIUrl":"10.1001/jamanetworkopen.2025.0802","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"8 3","pages":"e250802"},"PeriodicalIF":10.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA Network Open
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1